Paul Francis Miller Net Worth

The estimated Net Worth of Paul Francis Miller is at least $352 Mille dollars as of 12 February 2019. Paul Miller owns over 9,000 units of Synlogic Inc stock worth over $66,426 and over the last 7 years Paul sold SYBX stock worth over $285,480.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Miller SYBX stock SEC Form 4 insiders trading

Paul has made over 7 trades of the Synlogic Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Paul sold 9,000 units of SYBX stock worth $87,750 on 12 February 2019.

The largest trade Paul's ever made was selling 9,000 units of Synlogic Inc stock on 12 February 2019 worth over $87,750. On average, Paul trades about 3,375 units every 30 days since 2018. As of 12 February 2019 Paul still owns at least 48,135 units of Synlogic Inc stock.

You can see the complete history of Paul Miller stock trades at the bottom of the page.

What's Paul Miller's mailing address?

Paul's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.

Insiders trading at Synlogic Inc

Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.

What does Synlogic Inc do?

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre

Complete history of Paul Miller stock trades at Synlogic Inc

Synlogic Inc executives and stock owners

Synlogic Inc executives and other stock owners filed with the SEC include:

• Aoife Brennan,
  President, Chief Executive Officer, Director
• Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc,
  Pres, CEO & Director
• Antoine Awad,
  Chief Operating Officer
• Richard Riese,
  Chief Medical Officer
• Patricia Hurter,
  Independent Director
• Peter Barrett,
  Independent Chairman of the Board
• Richard Shea,
  Independent Director
• Edward Mathers,
  Independent Director
• Nick Leschly,
  Independent Director
• Chau Khuong,
  Independent Director
• Michael Burgess,
  Independent Director
• Michael Slater,
  Head of Regulatory Affairs
• David Hava,
  Chief Scientific Officer
• Gregg Beloff,
  Interim Chief Financial Officer
• Ajay Munshi,
  VP of Corp. Devel.
• Adam Thomas,
  Chief People Officer & Sec.
• Michael Jensen,
  Chief Financial Officer
• Dr. Timothy K. Lu M.D., Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Michael Conlon,
  VP of Corp. Devel.
• Brendan St. Amant,
  Head of Legal
• Daniel Rosan,
  Sr. VP & Head of Investor Relations
• Dr. Elizabeth Wolffe,
  Head of Investor Relations & Corp. Communications
• Dr. David L. Hava Ph.D.,
  Chief Scientific Officer
• Gregg D. Beloff J.D., M.B.A.,
  Interim Chief Financial Officer
• Dr. James J. Collins Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Timothy K. Lu,
  Co-Founder
• Todd Shegog,
  See Remarks
• Scott D Sandell,
  10% owner
• Ravi Viswanathan,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Forest Baskett,
  10% owner
• Michael Powell,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• M James Barrett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Jose Carlos Gutierrez Ramos,
  See Remarks
• Paul Francis Miller,
  Chief Scientific Officer
• Scott Eric Plevy,
  Chief Scientific Officer
• Michael Vangsted Jensen,
  Chief Financial Officer
• Antoine Awad,
  Chief Operating Officer
• Michael Thomas Heffernan,
  
• Lisa Kelly Croswell,
  
• James P Flynn,
  
• Mary Beth Dooley,
  Head of Finance